{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:59:41Z","timestamp":1777406381996,"version":"3.51.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,6,23]],"date-time":"2011-06-23T00:00:00Z","timestamp":1308787200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00270-011-0204-0","type":"journal-article","created":{"date-parts":[[2011,6,22]],"date-time":"2011-06-22T17:34:20Z","timestamp":1308764060000},"page":"30-42","source":"Crossref","is-referenced-by-count":32,"title":["Antiplatelet and Anticoagulant Drugs in Interventional Radiology"],"prefix":"10.1007","volume":"35","author":[{"given":"Alexander","family":"Altenburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Haage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,23]]},"reference":[{"issue":"Suppl 1","key":"204_CR1","first-page":"S63","volume":"33","author":"InterSociety Consensus for the Management of Peripheral Arterial Disease (TASC II)","year":"2007","unstructured":"InterSociety Consensus for the Management of Peripheral Arterial Disease (TASC II) (2007) Eur J Vasc Endovasc Surg 33(Suppl 1):S63","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1","key":"204_CR2","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.ahj.2006.10.010","volume":"153","author":"JT Brandt","year":"2007","unstructured":"Brandt JT, Payne CD, Wiviott SD, Weerakkody G et al (2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153(1):e9\u2013e16","journal-title":"Am Heart J"},{"issue":"25","key":"204_CR3","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Trenk D, Frelinger AL, O\u2019Donoghue M et al (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planed percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolyses in Myocardial Infarction 44 trial. Circulation 116(25):2923\u20132932","journal-title":"Circulation"},{"issue":"20","key":"204_CR4","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001\u20132015","journal-title":"N Engl J Med"},{"issue":"13","key":"204_CR5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jacc.2010.02.072","volume":"56","author":"DJ Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Saucedo JF, Deraad R et al (2010) Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56(13):1017\u20131023","journal-title":"J Am Coll Cardiol"},{"key":"204_CR6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Dudaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045\u20131057","journal-title":"N Engl J Med"},{"key":"204_CR7","unstructured":"Lammer J (2007) Clinical practice in interventional radiology \u2013 from the CIRSE task force on clinical practice in IR, vol. I:63"},{"key":"204_CR8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antiplatelet Trialists\u2019 Collaboration","year":"2002","unstructured":"Antiplatelet Trialists\u2019 Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, MI, and stroke in high-risk patients. Br Med J 324:71\u201386","journal-title":"Br Med J"},{"key":"204_CR9","first-page":"232","volume":"231","author":"J Vane","year":"1971","unstructured":"Vane J (1971) Inhibition of prostaglandin biosynthesis as a mechanism of action of ASA-like drugs. Nature 231:232\u2013235","journal-title":"Nature"},{"key":"204_CR10","first-page":"235","volume":"231","author":"JB Smith","year":"1971","unstructured":"Smith JB, Willis AL (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nature 231:235\u2013237","journal-title":"Nature"},{"key":"204_CR11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","volume":"56","author":"GJ Roth","year":"1975","unstructured":"Roth GJ, Majerus PW (1975) The mechanism of the effect of ASA on human platelets. Acetylation of a particular fraction protein. J Clin Invest 56:624\u2013632","journal-title":"J Clin Invest"},{"key":"204_CR12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","volume":"23","author":"K Schror","year":"1997","unstructured":"Schror K (1997) Aspirin and platelets: the antiplatelet actions of ASA and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 23:349\u2013355","journal-title":"Semin Thromb Hemost"},{"key":"204_CR13","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195155648.001.0001","volume-title":"Fibrinolytic and antithrombotic therapy","author":"RC Becker","year":"2006","unstructured":"Becker RC, Spencer FA (2006) Fibrinolytic and antithrombotic therapy. Oxford University Press, Oxford, UK"},{"key":"204_CR14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(68)92228-9","volume":"1","author":"JR O\u2019Brien","year":"1968","unstructured":"O\u2019Brien JR (1968) Effects of salicylates on human platelets. Lancet 1:779\u2013783","journal-title":"Lancet"},{"key":"204_CR15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2008.12.019","volume":"7","author":"E Smecuol","year":"2009","unstructured":"Smecuol E, Sanchez M, Suarez A et al (2009) Low-dose ASA affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 7:524\u2013529","journal-title":"Clin Gastroenterol Hepatol"},{"key":"204_CR16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000006871","volume":"91","author":"O Schaefer","year":"1999","unstructured":"Schaefer O, Gore J (1999) Aspirin sensitivity: the role for ASA challenge and desensitization in post MI patients. Cardiology 91:8\u201313","journal-title":"Cardiology"},{"key":"204_CR17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.amjcard.2004.10.022","volume":"95","author":"S Silberman","year":"2005","unstructured":"Silberman S, Neukirch-Stop C, Steg PG (2005) Rapid desensitization procedure for patients with ASA hypersensity undergoing coronary stenting. Am J Cardiol 95:509\u2013510","journal-title":"Am J Cardiol"},{"key":"204_CR18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","volume":"101","author":"EH Awtry","year":"2000","unstructured":"Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101:1206\u20131218","journal-title":"Circulation"},{"key":"204_CR19","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","volume":"108","author":"RJ Peters","year":"2003","unstructured":"Peters RJ, Mehzta SR, Fox KA et al (2003) Effects of ASA dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: oberservations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108:1682\u20131687","journal-title":"Circulation"},{"key":"204_CR20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(77)91197-7","volume":"1","author":"PM Mannucci","year":"1977","unstructured":"Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) A new pharmacological approach to the management of haemophilia and von Willebrand disease. Lancet 1:869\u2013872","journal-title":"Lancet"},{"key":"204_CR21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bmj.328.7438.477","volume":"328","author":"GJ Hankey","year":"2004","unstructured":"Hankey GJ, Eikelboom JW (2004) Aspirin resistance. Br Med J 328:477\u2013479","journal-title":"Br Med J"},{"issue":"1","key":"204_CR22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0091270007310379","volume":"48","author":"FM Gengo","year":"2008","unstructured":"Gengo FM, Rubin L, Robson M, Rainka M et al (2008) Effects of ibuprofen on the magnitude and duration of ASA\u2019s inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol 48(1):117\u2013122","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"204_CR23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1476-5381.2009.00243.x","volume":"157","author":"MP Schuijt","year":"2009","unstructured":"Schuijt MP, Huntjens-Fleuren HW, de Metz M, Vollaard EJ (2009) The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol 157(6):931\u2013934.","journal-title":"Br J Pharmacol"},{"key":"204_CR24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/0091270007313324","volume":"48","author":"FM Gengo","year":"2008","unstructured":"Gengo FM, Rainka M, Robson M, Gengo MF, Forrest A, Hourihane M et al (2008) Prevalence of platelet nonresponsiveness to ASA in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol 48:335\u2013343","journal-title":"J Clin Pharmacol"},{"key":"204_CR25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","volume":"167","author":"JD Snoep","year":"2007","unstructured":"Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Huisman MV (2007) Association of laboratory-defined ASA resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167:1593\u20131599","journal-title":"Arch Intern Med"},{"key":"204_CR26","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","volume":"27","author":"AL Frelinger","year":"2006","unstructured":"Frelinger AL, Furman MI, Linden MD et al (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independend pathway: a 700-patient study of ASA resistance. Circulation 27:2888\u20132896","journal-title":"Circulation"},{"key":"204_CR27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee (1996) A randomised, blinded trial of clopidogrel versus ASA in patients at risk for ischemic events (CAPRIE). Lancet 348:1329\u20131339","journal-title":"Lancet"},{"key":"204_CR28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.103.3.363","volume":"103","author":"DL Bahatt","year":"2001","unstructured":"Bahatt DL, Chew DP, Hirsch AT et al (2001) Superiority of clopidogrel versus ASA in patients with prior cardiac surgery. Circulation 103:363\u2013368","journal-title":"Circulation"},{"key":"204_CR29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0038-1656322","volume":"68","author":"C Gachet","year":"1992","unstructured":"Gachet C, Savi P, Ohlmann P et al (1992) ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes\u2015an effect selectively blocked by the thienopyridin clopidogrel. Thromb Haemost 68:79\u201383","journal-title":"Thromb Haemost"},{"key":"204_CR30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","volume":"409","author":"G Hollopter","year":"2001","unstructured":"Hollopter G, Jantzen HM, Cincent D et al (2001) Identification of the platelet ADP receptor targeted by antithombotic drugs. Nature 409:202\u2013207","journal-title":"Nature"},{"issue":"Suppl 2","key":"204_CR31","first-page":"25","volume":"25","author":"H Caplain","year":"1999","unstructured":"Caplain H, Donat F, Gaud C, Necciari J (1999) Pharmacokinetics of clopidogrel. Semin Thromb Hemost 25(Suppl 2):25\u201328","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 2","key":"204_CR32","first-page":"77","volume":"25","author":"JD Easton","year":"1999","unstructured":"Easton JD (1999) Clinical aspects of the use of clopidogrel, a new antiplatelet agent. Semin Thromb Hemost. 25(Suppl 2):77\u201382","journal-title":"Semin Thromb Hemost."},{"issue":"9","key":"204_CR33","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jacc.2005.01.030","volume":"45","author":"PA Gurbel","year":"2005","unstructured":"Gurbel PA, Bliden KP, Hayes KM et al (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high posttreatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45(9):1392\u20131396","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"204_CR34","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2007.05.048","volume":"100","author":"M Lotrionte","year":"2007","unstructured":"Lotrionte M, Biondi-Zoccai GG, Agostoni P et al (2007) Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 100(8):1199\u20131206","journal-title":"Am J Cardiol"},{"key":"204_CR35","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","volume":"53","author":"D Sibbing","year":"2009","unstructured":"Sibbing D, Braun S, Morath T et al (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53:849\u2013856","journal-title":"J Am Coll Cardiol"},{"key":"204_CR36","first-page":"1386","volume":"39","author":"B Leith\u00e4user","year":"2008","unstructured":"Leith\u00e4user B, Zielske D, Seyfert UT, Jung F (2008) Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc 39:1386\u20131391","journal-title":"Clin Hemorheol Microcirc"},{"key":"204_CR37","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","volume":"334","author":"A Schornig","year":"1996","unstructured":"Schornig A, Neumann FJ, Kastrati A et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084\u20131089","journal-title":"N Engl J Med"},{"key":"204_CR38","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","volume":"98","author":"P Urban","year":"1998","unstructured":"Urban P, Macaya C, Rupprecht H-J, for the MATTIS Investigators et al (1998) Randomized evaluation of anticoagulant versus antiplatelet therapy after coronary stent implantation in high-risk patients. The multicenter ASA and ticlopidine trial after coronary stenting (MATTIS). Circulation 98:2126\u20132132","journal-title":"Circulation"},{"key":"204_CR39","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to ASA in patients with acute coronary syndromes without ST-segment increase. N Engl J Med 345:494\u2013502","journal-title":"N Engl J Med"},{"key":"204_CR40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/eurheartj\/ehi138","volume":"26","author":"S Silber","year":"2005","unstructured":"Silber S, Albertsson P, Avil\u00e9s F et al (2005) Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26:804\u2013847","journal-title":"Eur Heart J"},{"key":"204_CR41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.105.170815","volume":"113","author":"SC Smith Jr","year":"2006","unstructured":"Smith SC Jr, Feldman TE, Hirshfeld JW et al (2006) ACC\/AHA Task Force on Practice Guidelines; ACC\/AHA\/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113:156\u2013175","journal-title":"Circulation"},{"key":"204_CR42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejvs.2005.01.012","volume":"29","author":"FM McKevitt","year":"2005","unstructured":"McKevitt FM, Randall MS, Cleveland TJ et al (2005) The benefits of combined antiplatelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg 29:522\u2013527","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"204_CR43","unstructured":"Clinical Practice in Interventional Radiology (2007) From the CIRSE Task Force on Clinical Practice in IR. Volume I:681"},{"key":"204_CR44","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1212\/01.wnl.0000216141.01262.77","volume":"66","author":"J-H Buhk","year":"2006","unstructured":"Buhk J-H, Wellmer A, Knauth M (2006) Late in-stent thrombosis following carotid angioplasty and stenting. Neurology 66:1594\u20131596","journal-title":"Neurology"},{"key":"204_CR45","first-page":"131","volume":"30","author":"PP Cacoub","year":"2009","unstructured":"Cacoub PP, Bhatt DL, Steg PG et al (2009) Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 30:131\u2013132","journal-title":"Eur Heart J"},{"key":"204_CR46","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.amjcard.2009.01.003","volume":"103","author":"MHU Usman","year":"2009","unstructured":"Usman MHU, Notaro LA, Nagarakanti R et al (2009) Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol 103:1107\u20131112","journal-title":"Am J Cardiol"},{"key":"204_CR47","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0002-9149(03)00012-2","volume":"91","author":"PA Horwitz","year":"2003","unstructured":"Horwitz PA, Berlin JA, Sauer WH, Laskey WK, Krone RJ, Kimmel SE, Registry Committee of the Society for Cardiac Angiography Interventions (2003) Bleeding risk of platelet glycoprotein IIb\/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry). Am J Cardiol 91:803\u2013806","journal-title":"Am J Cardiol"},{"key":"204_CR48","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1182\/blood-2002-11-3566","volume":"102","author":"RA Reiter","year":"2003","unstructured":"Reiter RA, Mayr F, Blazicek H, Galehr E (2003) Demopressin antagonizes the in vitro platelet dysfunction induced by GP IIb\/IIIa inhibitors and ASA. Blood 102:4594\u20134599","journal-title":"Blood"},{"issue":"1","key":"204_CR49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00270-005-0266-y","volume":"31","author":"G Tepe","year":"2008","unstructured":"Tepe G, Wiskirchen J, Pereira P et al (2008) GP IIb\/IIIa blockade during peripheral artery interventions. CVIR 31(1):8\u201313","journal-title":"CVIR"},{"key":"204_CR50","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0002-9149(03)00816-6","volume":"92","author":"DF Kong","year":"2003","unstructured":"Kong DF, Hasselblad V, Harrington RA et al (2003) Meta-analysis of survival with platelet glycoprotein IIb\/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 92:651\u2013655","journal-title":"Am J Cardiol"},{"issue":"6","key":"204_CR51","first-page":"266","volume":"20","author":"NW Shammas","year":"2008","unstructured":"Shammas NW, Dippel EJ, Shammas GA et al (2008) Utilization of GP IIb\/IIIa inhibitors in peripheral percutanous interventions: current applications and in-hospital outcomes at a tertiary referral center. J Invasive Cardiol 20(6):266\u2013269","journal-title":"J Invasive Cardiol"},{"issue":"3","key":"204_CR52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.RVI.0000116193.44877.0F","volume":"15","author":"K Ouriel","year":"2004","unstructured":"Ouriel K, Castaneda F, McNamara T et al (2004) Reteplase monotherapy and reteplase\/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial. J Vasc Intervent Radiol 15(3):229\u2013238","journal-title":"J Vasc Intervent Radiol"},{"key":"204_CR53","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ccd.20573","volume":"66","author":"KJ Rocha-Singh","year":"2005","unstructured":"Rocha-Singh KJ, Rutherford J (2005) Glycoprotein IIb\/IIIa inhibition with eptifibatide in percutaneous intervention for symptomatic peripheral vascular disease: the circulate pilot trial. Catheter Cardiovasc Interv 66:470\u2013473","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"204_CR54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/j.tvir.2005.10.004","volume":"8","author":"AB McIff","year":"2005","unstructured":"McIff AB (2005) Worksheets for use while performing carotid stenting or stroke intervention. Tech Vasc Interv Radiol 8(3):129\u2013130","journal-title":"Tech Vasc Interv Radiol"},{"key":"204_CR55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-0038-1646990","volume":"60","author":"S Beguin","year":"1988","unstructured":"Beguin S, Lindhout T, Hemker HC (1988) The mode of action of heparin in plasma. Thromb Haemost 60:457\u2013462","journal-title":"Thromb Haemost"},{"key":"204_CR56","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","volume":"103","author":"DP Chew","year":"2001","unstructured":"Chew DP, Bhatt DL, Lincoff AM et al (2001) Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 103:961\u2013966","journal-title":"Circulation"},{"key":"204_CR57","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2004-04-1544","volume":"105","author":"L Rauova","year":"2005","unstructured":"Rauova L, Poncz M, McKenzie S, Reilly MP, Arepally G, Weisel JW (2005) Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105:131\u2013138","journal-title":"Blood"},{"key":"204_CR58","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1046\/j.1538-7836.2003.00270.x","volume":"1","author":"BH Chong","year":"2003","unstructured":"Chong BH (2003) Heparin-induced thrombocytopenia. J Thromb Haemost 1:1471\u20131478","journal-title":"J Thromb Haemost"},{"key":"204_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(03)00030-6","volume":"109","author":"MM Samam","year":"2003","unstructured":"Samam MM, Gerotziafas GT (2003) Evaluation of the pharmacological properties and clinical results of the systhetic pentasaccharide fondaparinux. Thromb Res 109:1\u201311","journal-title":"Thromb Res"},{"key":"204_CR60","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0038-1648875","volume":"72","author":"CN Berry","year":"1994","unstructured":"Berry CN, Girardot C, Lecoffre C, Lunven C (1994) Effects of the synthetic thrombin inhibitor argatraban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 72:381\u2013386","journal-title":"Thromb Haemost"},{"issue":"3","key":"204_CR61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.RVI.0000151260.74519.CA","volume":"16","author":"SH Duda","year":"2005","unstructured":"Duda SH, Bosiers M, Lammer J et al (2005) Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease. The SIROCCO II trial. J Vasc Interv Radiol 16(3):331\u2013338","journal-title":"J Vasc Interv Radiol"},{"key":"204_CR62","volume-title":"The Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 24-month update","author":"D Dake","year":"2011","unstructured":"Dake D (2011) The Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 24-month update. LINC Congress, Leipzig, Grmany"},{"key":"204_CR63","first-page":"1077","volume":"19","author":"ML Linenberger","year":"2005","unstructured":"Linenberger ML, Wittkowsky AK (2005) Thromboembolic complications of malignancy. Part 1: risks. Oncology (Williston Park) 19:1077\u20131084","journal-title":"Oncology (Williston Park)"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-011-0204-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00270-011-0204-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-011-0204-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T04:53:07Z","timestamp":1637902387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00270-011-0204-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,23]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["204"],"URL":"https:\/\/doi.org\/10.1007\/s00270-011-0204-0","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,23]]}}}